Volume 146, Issue 2, Pages e6 (February 2014)

Slides:



Advertisements
Similar presentations
Volume 152, Issue 5, Pages e1 (April 2017)
Advertisements

Volume 149, Issue 6, Pages (November 2015)
Volume 146, Issue 2, Pages e6 (February 2014)
The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis  Janneke van Grinsven, Sandra van Brunschot  Gastroenterology 
Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B  Emmet B. Keeffe, Stefan Zeuzem,
Volume 139, Issue 4, Pages (October 2010)
Volume 139, Issue 5, Pages e1 (November 2010)
Gastrointestinal Stromal Tumors: Disease and Treatment Update
Effects of Community Screening for Helicobacter pylori: 13-Year Follow-Up Evaluation of a Randomized Controlled Trial  Maria Bomme, Jane Møller Hansen,
Christoph Lübbert, Babett Holler  Gastroenterology 
The Value of a 24/7 Online Nationwide Multidisciplinary Expert Panel for Acute Necrotizing Pancreatitis  Janneke van Grinsven, Sandra van Brunschot  Gastroenterology 
Covering the Cover Gastroenterology
Volume 149, Issue 6, Pages (November 2015)
New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
Volume 139, Issue 4, Pages (October 2010)
Effectiveness of Hepatitis B Treatment in Clinical Practice
Volume 153, Issue 4, Pages (October 2017)
Volume 146, Issue 3, Pages e1 (March 2014)
Outcomes Among Living Liver Donors
Volume 143, Issue 3, Pages e5 (September 2012)
Impact of IL28B Genotype on the Early and Sustained Virologic Response in Treatment- Naïve Patients With Chronic Hepatitis C  Albert Friedrich Stättermayer,
Ira J. Fox, Stephen C. Strom  Gastroenterology 
Volume 149, Issue 4, Pages e1 (October 2015)
A Sustained Viral Response Is Associated With Reduced Liver-Related Morbidity and Mortality in Patients With Hepatitis C Virus  Amit G. Singal, Michael.
Volume 141, Issue 3, Pages e1 (September 2011)
Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection  Steven L. Flamm, Eric Lawitz,
Volume 152, Issue 6, Pages e2 (May 2017)
Volume 151, Issue 4, Pages e1 (October 2016)
Volume 138, Issue 2, Pages e1 (February 2010)
Volume 140, Issue 2, Pages e1 (February 2011)
Covering the Cover Gastroenterology
Volume 153, Issue 3, Pages e16-e17 (September 2017)
Volume 150, Issue 4, Pages (April 2016)
Volume 146, Issue 3, Pages e3 (March 2014)
Report of an International Workshop: Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B  Emmet B. Keeffe, Stefan Zeuzem,
Volume 154, Issue 4, Pages (March 2018)
Metoclopramide Nasal Spray Reduces Symptoms of Gastroparesis in Women, but not Men, With Diabetes: Results of a Phase 2B Randomized Study  Henry P. Parkman,
Volume 155, Issue 5, Pages e2 (November 2018)
Volume 141, Issue 5, Pages (November 2011)
Volume 146, Issue 7, Pages e3 (June 2014)
Volume 152, Issue 1, Pages e4 (January 2017)
Volume 143, Issue 5, Pages e6 (November 2012)
A. Sidney Barritt, Michael W. Fried  Gastroenterology 
Volume 130, Issue 4, Pages (April 2006)
The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.
Gastrointestinal Stromal Tumors: Disease and Treatment Update
Volume 141, Issue 1, Pages e1 (July 2011)
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir  Zobair.
Impact of New Hepatitis C Treatments in Different Regions of the World
Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C  Zobair M. Younossi,
Volume 151, Issue 1, Pages e6 (July 2016)
Laura Rotundo, Sushil Ahlawat  Gastroenterology 
Volume 138, Issue 7, Pages (June 2010)
Rafael Esteban, Maria Buti  Gastroenterology 
Volume 145, Issue 4, Pages e3 (October 2013)
Volume 150, Issue 2, Pages (February 2016)
Volume 148, Issue 3, Pages e4 (March 2015)
Volume 149, Issue 6, Pages (November 2015)
Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C  Gowtham A. Rao, Prashant K. Pandya  Gastroenterology 
Volume 143, Issue 3, Pages e5 (September 2012)
Alessio Aghemo, Maria Francesca Donato  Gastroenterology 
Volume 147, Issue 2, Pages e1 (August 2014)
Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection  Harald Farnik, Christian M. Lange,
Volume 155, Issue 6, Pages (December 2018)
Volume 139, Issue 6, Pages e1 (December 2010)
Volume 139, Issue 5, Pages (November 2010)
Electronic Clinical Challenges and Images in GI
Electronic Clinical Challenges and Images in GI
The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.
A Rare Tumor of the Liver With a Sudden Presentation
Presentation transcript:

Volume 146, Issue 2, Pages 430-441.e6 (February 2014) Simeprevir Increases Rate of Sustained Virologic Response Among Treatment- Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial  Stefan Zeuzem, Thomas Berg, Edward Gane, Peter Ferenci, Graham R. Foster, Michael W. Fried, Christophe Hezode, Gideon M. Hirschfield, Ira Jacobson, Igor Nikitin, Paul J. Pockros, Fred Poordad, Jane Scott, Oliver Lenz, Monika Peeters, Vanitha Sekar, Goedele De Smedt, Rekha Sinha, Maria Beumont-Mauviel  Gastroenterology  Volume 146, Issue 2, Pages 430-441.e6 (February 2014) DOI: 10.1053/j.gastro.2013.10.058 Copyright © 2014 AGA Institute Terms and Conditions

Figure 1 SVR24 by prior response to PegIFN/RBV and HCV genotype-1 subtype. aDuration groups pooled. SMV, simeprevir. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Figure 2 SVR24 by prior response to PegIFN/RBV and METAVIR score. aDuration groups pooled. SMV, simeprevir. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Figure 3 Treatment outcomes and reasons for not achieving SVR24. SMV, simeprevir. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Supplementary Figure 1 Study design. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Supplementary Figure 2 CONSORT flow diagram. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Supplementary Figure 3 SVR24 according to IL28B (rs12979860) genotype. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Supplementary Figure 4 Mean (A) total, (B) direct, and (C) indirect bilirubin during the 72-week study period. (D) Mean total bilirubin values for patients with METAVIR score F4. Horizontal lines in each figure represent the upper and lower limits of normal, respectively. Gastroenterology 2014 146, 430-441.e6DOI: (10.1053/j.gastro.2013.10.058) Copyright © 2014 AGA Institute Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.